Loading...

Argos Therapeutics

DB:77AA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
77AA
DB
$2M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • Argos Therapeutics has significant price volatility in the past 3 months.
77AA Share Price and Events
7 Day Returns
0%
DB:77AA
6%
DE Biotechs
4.2%
DE Market
1 Year Returns
-97.7%
DB:77AA
2.5%
DE Biotechs
-9.9%
DE Market
77AA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Argos Therapeutics (77AA) 0% 0% 1.9% -97.7% -99.9% -
DE Biotechs 6% -5.5% -7.8% 2.5% 69.1% 83.1%
DE Market 4.2% -4.1% -6.7% -9.9% 25.7% 52.5%
1 Year Return vs Industry and Market
  • 77AA underperformed the Biotechs industry which returned 2.5% over the past year.
  • 77AA underperformed the Market in Germany which returned -9.9% over the past year.
Price Volatility
77AA
Industry
5yr Volatility vs Market
Related Companies

77AA Value

 Is Argos Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Argos Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Argos Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Argos Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.055.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Argos Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Argos Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:77AA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-2.53
OTCPK:ARGS Share Price ** OTCPK (2018-08-07) in USD $0.14
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 29.25x
Germany Market PE Ratio Median Figure of 411 Publicly-Listed Companies 18.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Argos Therapeutics.

DB:77AA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:ARGS Share Price ÷ EPS (both in USD)

= 0.14 ÷ -2.53

-0.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Argos Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Argos Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Argos Therapeutics's expected growth come at a high price?
Raw Data
DB:77AA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.57x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Argos Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Argos Therapeutics's assets?
Raw Data
DB:77AA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $-0.77
OTCPK:ARGS Share Price * OTCPK (2018-08-07) in USD $0.14
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.46x
Germany Market PB Ratio Median Figure of 549 Publicly-Listed Companies 1.88x
DB:77AA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:ARGS Share Price ÷ Book Value per Share (both in USD)

= 0.14 ÷ -0.77

-0.19x

* Primary Listing of Argos Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Argos Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 77AA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Argos Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Argos Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Argos Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

77AA Future Performance

 How is Argos Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Argos Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Argos Therapeutics expected to grow at an attractive rate?
  • Unable to compare Argos Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Argos Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Argos Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:77AA Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:77AA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:77AA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:77AA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 8 -22 -17
2018-03-31 8 -26 -19
2017-12-31 2 -35 -41
2017-09-30 0 -41 -54
2017-06-30 0 -43 -60
2017-03-31 1 -46 -64
2016-12-31 1 -41 -53
2016-09-30 1 -45 -55
2016-06-30 1 -53 -63
2016-03-31 0 -56 -70
2015-12-31 1 -61 -75
2015-09-30 1 -60 -73

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Argos Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Argos Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:77AA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Argos Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:77AA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:77AA Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -2.53
2018-03-31 -4.22
2017-12-31 -13.45
2017-09-30 -23.72
2017-06-30 -29.73
2017-03-31 -35.05
2016-12-31 -33.14
2016-09-30 -41.09
2016-06-30 -55.93
2016-03-31 -66.13
2015-12-31 -73.12
2015-09-30 -72.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Argos Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 77AA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Argos Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Argos Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Argos Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Argos Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

77AA Past Performance

  How has Argos Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Argos Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Argos Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Argos Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Argos Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Argos Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Argos Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:77AA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 7.71 -16.55 10.54 18.09
2018-03-31 7.73 -18.61 10.72 19.29
2017-12-31 1.90 -40.58 12.18 21.66
2017-09-30 0.39 -54.04 14.35 26.69
2017-06-30 0.49 -60.22 14.48 31.48
2017-03-31 0.90 -64.29 15.19 35.52
2016-12-31 0.95 -53.03 14.20 37.11
2016-09-30 0.86 -55.23 12.42 41.98
2016-06-30 0.87 -63.06 12.09 49.87
2016-03-31 0.49 -70.06 11.61 56.79
2015-12-31 0.52 -74.79 11.01 62.05
2015-09-30 0.75 -73.45 10.45 61.54
2015-06-30 0.99 -68.47 10.08 57.31
2015-03-31 1.35 -60.85 9.04 51.65
2014-12-31 1.97 -54.17 8.60 45.36
2014-09-30 2.39 -46.45 7.74 38.97
2014-06-30 2.97 -46.42 6.44 31.60
2014-03-31 3.76 -40.22 5.52 27.27
2013-12-31 4.42 -33.87 4.66 23.99
2013-09-30 5.24 -27.80 4.00 20.89
2013-06-30 5.90 -16.80 3.83 24.47
2013-03-31 6.57 -13.17 5.05 20.24
2012-12-31 7.04 -10.82 6.14 16.92
2012-09-30 7.27 -15.18 6.95 15.06
2012-06-30 7.38 -16.22 6.65 3.66
2012-03-31 7.34 -20.72 5.16 6.58
2011-12-31 7.64 -21.00 3.70 12.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Argos Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Argos Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Argos Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Argos Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Argos Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

77AA Health

 How is Argos Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Argos Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Argos Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Argos Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Argos Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Argos Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Argos Therapeutics Company Filings, last reported 4 months ago.

DB:77AA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -8.14 18.94 12.13
2018-03-31 -3.18 19.13 17.02
2017-12-31 -9.23 19.46 15.19
2017-09-30 -16.97 26.86 9.37
2017-06-30 -20.57 22.30 9.34
2017-03-31 -13.77 16.20 11.14
2016-12-31 6.17 39.86 52.97
2016-09-30 20.13 41.24 69.28
2016-06-30 4.26 38.45 34.83
2016-03-31 -20.17 39.73 13.84
2015-12-31 -28.20 39.56 7.17
2015-09-30 -13.93 39.76 23.06
2015-06-30 4.73 27.93 30.56
2015-03-31 14.90 25.90 39.17
2014-12-31 31.35 23.21 56.24
2014-09-30 46.69 22.21 69.52
2014-06-30 60.56 7.38 71.80
2014-03-31 71.90 7.22 83.38
2013-12-31 37.89 7.06 46.96
2013-09-30 45.55 9.06 54.22
2013-06-30 -2.60 0.06 3.35
2013-03-31 7.23 0.08 12.36
2012-12-31 7.23 0.08 12.36
2012-09-30
2012-06-30
2012-03-31 -18.63 10.38 2.00
2011-12-31 -18.63 10.38 2.00
  • Argos Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Argos Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Argos Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.
  • Argos Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -27.7% each year.
X
Financial health checks
We assess Argos Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Argos Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

77AA Dividends

 What is Argos Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Argos Therapeutics dividends.
If you bought €2,000 of Argos Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Argos Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Argos Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:77AA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:77AA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Argos Therapeutics has not reported any payouts.
  • Unable to verify if Argos Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Argos Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Argos Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Argos Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Argos Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Argos Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

77AA Management

 What is the CEO of Argos Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Abbey
COMPENSATION $2,045,548
AGE 56
TENURE AS CEO 8.8 years
CEO Bio

Mr. Jeffrey D. Abbey, also known as Jeff, M.B.A., J.D., Esq. has been the Chief Executive Officer and President of Argos Therapeutics, Inc. (formerly MERIX Bioscience,Inc) since February 2010. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. Mr. Abbey served as a Chief Business Officer of Argos Therapeutics, Inc. from January 2009 to February 2010. Mr. Abbey served as Vice President of Business Development of Argos Therapeutics, Inc. since February 2004 until January 2009. Mr. Abbey joined Argos Therapeutics in September 2002. Before joining Argos, Mr. Abbey served as a Vice President of Business Development and Finance at Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a Partner of Ehrenreich Eilenberg & Krause, where he served as business counsel for a number of life sciences and other emerging technology companies. Mr. Abbey has been a Director of North Carolina Biosciences Organization (NCBIO) since October 26, 2016. Mr. Abbey has been a Director at Argos Therapeutics, Inc. since February 2010. Mr. Abbey holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Argos Therapeutics management team in years:

8
Average Tenure
55
Average Age
  • The average tenure for the Argos Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jeff Abbey

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
8.8 yrs

Richard Katz

TITLE
VP & CFO
COMPENSATION
$783K
AGE
54
TENURE
2.3 yrs

Charles Nicolette

TITLE
Chief Scientific Officer and VP of Research & Development
COMPENSATION
$1M
AGE
56
TENURE
10.9 yrs

Bill Wofford

TITLE
Secretary

Lori Harrelson

TITLE
Vice President of Finance
COMPENSATION
$418K
AGE
49
TENURE
7.3 yrs

Fred Hutchison

TITLE
Assistant Secretary
Board of Directors Tenure

Average tenure and age of the Argos Therapeutics board of directors in years:

3.3
Average Tenure
56
Average Age
  • The tenure for the Argos Therapeutics board of directors is about average.
Board of Directors

Hubert Birner

TITLE
Chairman
COMPENSATION
$118K
AGE
52
TENURE
13.8 yrs

Jeff Abbey

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
8.8 yrs

Charles Drake

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs

Robert Figlin

TITLE
Member of Scientific Advisory Board

Bernard Fox

TITLE
Member of Scientific Advisory Board
AGE
64

Gerald Linette

TITLE
Member of Scientific Advisory Board

Thomas Schwaab

TITLE
Member of Scientific Advisory Board

Robert Seder

TITLE
Member of Scientific Advisory Board

Bob Carey

TITLE
Director
COMPENSATION
$123K
AGE
59
TENURE
3.2 yrs

Igor Krol

TITLE
Director
COMPENSATION
$75K
AGE
44
TENURE
2.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (USD) Value (USD)
X
Management checks
We assess Argos Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Argos Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

77AA News

External News
Loading...
Simply Wall St News

77AA Company Info

Map
Description

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Details
Name: Argos Therapeutics, Inc.
77AA
Exchange: DB
Founded: 1997
$1,333,987
10,586,661
Website: http://www.argostherapeutics.com
Address: Argos Therapeutics, Inc.
4233 Technology Drive,
Durham,
North Carolina, 27704,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK ARGS Common Stock Pink Sheets LLC US USD 07. Feb 2014
DB 77AA Common Stock Deutsche Boerse AG DE EUR 07. Feb 2014
Number of employees
Current staff
Staff numbers
39
Argos Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/04 18:41
End of day share price update: 2018/08/07 00:00
Last estimates confirmation: 2018/04/02
Last earnings filing: 2018/08/20
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.